HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

5th Edition of Cardiology World Conference

September 5-7, 2024 | Madrid, Spain

September 05 -07, 2024 | Madrid, Spain
Cardio 2023

Mayur Mayabhate

Mayur Mayabhate, Speaker at Cardiology Conferences
Alkem Laboratories Ltd, India
Title : Effectiveness and safety of sacubitril/valsartan in Indian patients with heart failure in the real-world setting


Introduction: Sacubitril/valsartan in one of the pillars of fantastic four and has been established as an effective treatment for heart failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known about its use or impact in real-world practice in Indian population.
Methods: This retrospective study was conducted on adult patients newly diagnosed with HF (class I-III, as per physician discretion) and treated with sacubitril/valsartan (Tab. Sacuval, Alkem Laboratories Ltd) between Feb - April 2023 in respective doses for at least 3 months. The captured data included demographic profile, blood pressure (BP), eGFR and comorbidities.  Moreover, changes in left ventricular ejection fraction (LVEF), NT-ProBNP levels, clinical symptoms (assessed on scale of 1-10, 10 being with highest severity) were evaluated post treatment with Sacubitril/valsartan in real world settings.
Results: Out of 60 patients eligible for the study, 57% were males and 43% were females. Mean body weight was 60.26±7.00 kg, while mean BP was 130/81 mmHg. 60% patients were having both type 2 diabetes and hypertension as comorbidity. There was 23% improvement in LVEF (from mean LVEF of 34 to 42, P<0.05), with significant decrease in NT-ProBNP levels (mean 1220.5 pg/ml to 118.1 pg/ml, P<0.001) after treatment with Sacubitril/valsartan for 3 months, resulted in marked improvement in clinical symptoms of breathlessness (mean score decreased from 6 to 2, p<0.05), edema (mean score deceased from 5.5 to 1.8, p<0.05) and palpitations (mean score decreased from 2.4 to 1.1, p<0.05. Furthermore, modest decrease in mean BP was also noted (from 130/81 mmHg to 119/76 mmHg. 50 mg BD was most commonly used dose of sacubitril/valsartan (70% patients), followed by 100 mg BD (25% patients). Treatment with sacubitril/valsartan was well tolerated, with <5% patients reporting hypotension.
Conclusion: The findings of this real-world study suggest sacubitril/valsartan was associated with increase in ejection fraction translating into symptomatic improvement in Indian patients of HF. Sacubitril/valsartan will continue to be of great value in clinician’s armamentarium in holistic HF management.

Audience Take Away Notes

  • To the best of our knowledge, this is the first study elucidating the effectiveness and safety of sacubitril/valsartan in patients, post patent expiry with availability of good quality generics at affordable cost.
  • Sacubitril/valsartan revolutionized the HF management with significant improvement in ejection fraction translating into improvement in clinical symptoms.
  • Contrary to western counterparts, Indian population has low SBP, low BMI, thus the dose of sacubitril/valsartan is the key to minimize chance of hypotension. We found that, 50 mg BD of sacubitril/valsartan is the most suitable dose for Indian population with good tolerability profile.


Dr. Mayur Mayabhate studied his MD from Indira Gandhi Govt. Medical College Nagpur India. He is currently heading the Medical Affairs Dept at Alkem Laboratories Mumbai, with more than a decade of experience under him in clinical research